A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
Hiroyuki FujiwaraKimio UshijimaShoji NagaoYuji TakeiMuneaki ShimadaMasashi TakanoKiyoshi YoshinoYoshiaki KawanoYasuyuki HirashimaSatoru NagaseShin NishioTadaaki NishikawaKimihiko ItoTadahiro ShojiEizo KimuraTadao TakanoToru SugiyamaJunzo KigawaKeiichi FujiwaraMitsuaki SuzukiPublished in: International journal of clinical oncology (2019)
PLDC and GC are both good treatment candidates for platinum-sensitive recurrent ovarian cancer patients; however, the dose intensity was lower for GC than for PLDC. PLDC had a more favorable risk-benefit profile than that of GC for patients.
Keyphrases
- phase ii
- phase iii
- open label
- clinical trial
- phase ii study
- double blind
- end stage renal disease
- placebo controlled
- ejection fraction
- newly diagnosed
- gas chromatography
- chronic kidney disease
- prognostic factors
- randomized controlled trial
- locally advanced
- combination therapy
- high resolution
- rectal cancer
- study protocol